EDDA Technology Introduces New FDA-Cleared IQQA -BodyImaging
PRINCETON, N.J: EDDA Technology, provider of real-time interactive quantitative imaging solutions has announced the company’s FDA clearance on IQQA- BodyImaging.
The new product will be latest addition to the IQQA Platform and Product Suite for imaging-guided cancer treatment. It is developed with a specific aim to maximize the utilization of multimodality imaging and its benefit for multiple stakeholders along the cycle of patient care, which include radiologists, interventional radiologists, surgeons, and oncologists.
The IQQA Platform enables a patient-specific, disease-targeted, and multidisciplinary approach to cancer treatment by supporting efficient collaboration for optimal workflow and treatment management with clinical depth and OnDemand accessibility.
The company is also demonstrating IQQA-Liver Multimodality, as part of the IQQA Product Suite. IQQA-Liver Multimodality is currently being used by physicians worldwide for real-time, interactive treatment planning and post-procedural assessment of liver diseases. IQQA-Liver Multimodality has been proven to provide significant time-saving and improved patient care.
"We are pleased to announce the launch of IQQA-BodyImaging, which significantly broadens our product and service offering to cover close to 50 percent of the world's cancer incidences," says Dr. Jianzhong Qian, president and CEO of EDDA Technology.